BioCentury
ARTICLE | Financial News

Aslan raises $23M in pre-IPO round

July 6, 2016 12:12 AM UTC

Cancer biotech Aslan Pharmaceuticals Pte. Ltd. (Singapore) raised $23 million in a series D round from new and existing investors. New investors included TopTaiwan, KGI VC, Ta Ya Ventures, Milestone Capital, Daiwa Taiwan-Japan Biotech Fund and China Galaxy. Existing investors included Sagamore BioVentures, Naga Capital and management.

Founder and CEO Carl Firth told BioCentury Aslan considers the financing to be a pre-IPO round, with the company planning to go public next year via an IPO in Taiwan. ...